Ocrelizumab-treated patients with relapsing multiple sclerosis show volume loss rates similar to healthy aging.

Shannon KolindLaura GaetanoHaz-Edine AssemlalCorrado BernasconiUlrike BonatiColm ElliottNiels HagenbuchStefano MagonDouglas L ArnoldAnthony Traboulsee

Published in: Multiple sclerosis (Houndmills, Basingstoke, England) (2023)

These findings are consistent with an important role of inflammation on overall tissue loss and the role of ocrelizumab in reducing this phenomenon.

Keyphrases

multiple sclerosis
white matter
oxidative stress
disease activity
systemic lupus erythematosus
newly diagnosed